These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23000597)

  • 21. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.
    Veerappan SG; O'Morain CA; Daly JS; Ryan BM
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1261-72. PubMed ID: 21521250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
    Lee LY; Sanderson JD; Irving PM
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of inflammatory bowel disease with corticosteroids.
    Katz JA
    Gastroenterol Clin North Am; 2004 Jun; 33(2):171-89, vii. PubMed ID: 15177533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial design in systemic lupus erythematosus.
    Dall'Era M; Wofsy D
    Curr Opin Rheumatol; 2006 Sep; 18(5):476-80. PubMed ID: 16896285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in biologic therapy for inflammatory bowel disease].
    Sostegni R; Pera A; Daperno M; Rocca R
    Recenti Prog Med; 2008 Jan; 99(1):10-8. PubMed ID: 18389866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Nielsen OH; Ainsworth MA
    N Engl J Med; 2013 Aug; 369(8):754-62. PubMed ID: 23964937
    [No Abstract]   [Full Text] [Related]  

  • 28. [New treatment options for inflammatory bowel diseases].
    Sipponen T; Färkkilä M; Kolho KL
    Duodecim; 2014; 130(14):1391-8. PubMed ID: 25158578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing the Impact of Randomized, Controlled Trials in Gastrointestinal Endoscopy.
    Elmunzer BJ
    Gastroenterology; 2015 Sep; 149(3):521-5. PubMed ID: 26226569
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparing guidelines for the treatment of inflammatory bowel disease.
    Hanauer SB; Kirsner JB
    Dig Dis; 2013; 31(3-4):360-2. PubMed ID: 24246988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions.
    Khanna R; Zou G; Feagan BG
    Inflamm Bowel Dis; 2018 Sep; 24(10):2155-2164. PubMed ID: 29788218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current issues in the design of clinical trials in IBD.
    Feagan BG
    Nestle Nutr Inst Workshop Ser; 2014; 79():19-28. PubMed ID: 25227292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multistage analysis strategy for a clinical trial to assess successively more stringent criteria for a primary endpoint with a low event rate.
    Li S; Hussey MA; Schwartz TA; Koch GG
    Pharm Stat; 2013; 12(2):65-73. PubMed ID: 23424092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment guidelines in inflammatory bowel disease: the Japanese perspectives.
    Matsuoka K; Hibi T
    Dig Dis; 2013; 31(3-4):363-7. PubMed ID: 24246989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Best (but oft-forgotten) practices: designing, analyzing, and reporting cluster randomized controlled trials.
    Brown AW; Li P; Bohan Brown MM; Kaiser KA; Keith SW; Oakes JM; Allison DB
    Am J Clin Nutr; 2015 Aug; 102(2):241-8. PubMed ID: 26016864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardisation of Study Protocols - Pros and Cons.
    D'Haens G
    J Crohns Colitis; 2016 Sep; 10 Suppl 2():S553-9. PubMed ID: 27604980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surrogate end points in secondary analyses of cardiovascular trials.
    Buhr KA
    Prog Cardiovasc Dis; 2012; 54(4):343-50. PubMed ID: 22226002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conducting research in rural primary care medicine: do we need more experimental research or guidance?
    Lionis C; Tatsioni A
    Rural Remote Health; 2012 Oct; 12(4):2267. PubMed ID: 23210462
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials.
    Feagan BG; McDonald JW; Koval JJ
    Gastroenterology; 1996 Jan; 110(1):275-83. PubMed ID: 8536868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons.
    Danese S; Schabel E; Masure J; Plevy S; Schreiber S
    J Crohns Colitis; 2016 Sep; 10 Suppl 2():S548-52. PubMed ID: 27604979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.